164 related articles for article (PubMed ID: 10577850)
1. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma.
Fosså A; Santoro A; Hiddemann W; Truemper L; Niederle N; Buksmaui S; Bonadonna G; Seeber S; Nowrousian MR
J Clin Oncol; 1999 Dec; 17(12):3786-92. PubMed ID: 10577850
[TBL] [Abstract][Full Text] [Related]
2. Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL.
el Aziz LM
Med Oncol; 2014 Nov; 31(11):244. PubMed ID: 25294423
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma.
Zlotnick M; Avigdor A; Ribakovsky E; Nagler A; Kedmi M
Acta Haematol; 2019; 141(2):84-90. PubMed ID: 30630175
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.
Dumontet C; Morschhauser F; Solal-Celigny P; Bouafia F; Bourgeois E; Thieblemont C; Leleu X; Hequet O; Salles G; Coiffier B
Br J Haematol; 2001 Jun; 113(3):772-8. PubMed ID: 11380469
[TBL] [Abstract][Full Text] [Related]
6. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.
Bai B; Huang HQ; Cai QQ; Wang XX; Cai QC; Lin ZX; Gao Y; Xia Y; Bu Q; Guo Y
Med Oncol; 2013 Mar; 30(1):350. PubMed ID: 23329307
[TBL] [Abstract][Full Text] [Related]
7. Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma.
Bernell P; Ohm L
Br J Haematol; 1998 Apr; 101(1):203-4. PubMed ID: 9576202
[TBL] [Abstract][Full Text] [Related]
8. [Gemcitabine in the treatment of relapsed or refractory non-Hodgkin's lymphoma].
Ma S; Sheng X; Luo R; Li A
Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):619-20. PubMed ID: 12667341
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of gemcitabine in patients with relapsed or refractory low-grade non-Hodgkin lymphoma.
Larson BJ; Waples JM; Pusateri A; Mendenhall NP; Lynch JW
Am J Clin Oncol; 2005 Apr; 28(2):165-8. PubMed ID: 15803011
[TBL] [Abstract][Full Text] [Related]
10. Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma.
Zhong DT; Shi CM; Chen Q; Huang JZ; Liang JG
Ann Hematol; 2012 Nov; 91(11):1757-63. PubMed ID: 22790106
[TBL] [Abstract][Full Text] [Related]
11. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
12. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM; Parker T
Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
[TBL] [Abstract][Full Text] [Related]
13. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma.
Venkatesh H; Di Bella N; Flynn TP; Vellek MJ; Boehm KA; Asmar L
Clin Lymphoma; 2004 Sep; 5(2):110-5. PubMed ID: 15453926
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-Based Treatment in Poor-Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma--a Multicenter Polish Experience.
Rybka J; Jurczak W; Giza A; Paszkiewicz-Kozik E; Kumiega B; Drozd-Sokołowska J; Butrym A; Kuliczkowski K; Wróbel T
Adv Clin Exp Med; 2015; 24(5):783-9. PubMed ID: 26768628
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma.
Emmanouilides C; Colovos C; Pinter-Brown L; Hernandez L; Schiller G; Territo M; Rosen P
Clin Lymphoma; 2004 Jun; 5(1):45-9. PubMed ID: 15245607
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study.
Santoro A; Bredenfeld H; Devizzi L; Tesch H; Bonfante V; Viviani S; Fiedler F; Parra HS; Benoehr C; Pacini M; Bonadonna G; Diehl V
J Clin Oncol; 2000 Jul; 18(13):2615-9. PubMed ID: 10893294
[TBL] [Abstract][Full Text] [Related]
17. Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial.
Jo JC; Baek JH; Lee JH; Joo YD; Bae SH; Lee JL; Lee JH; Kim DY; Lee WS; Ryoo HM; Choi Y; Kim H; Lee KH;
Asia Pac J Clin Oncol; 2016 Jun; 12(2):159-66. PubMed ID: 26956432
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
[TBL] [Abstract][Full Text] [Related]
19. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Anderson H; Lund B; Bach F; Thatcher N; Walling J; Hansen HH
J Clin Oncol; 1994 Sep; 12(9):1821-6. PubMed ID: 8083706
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.
Shepherd FA; Cormier Y; Burkes R; Evans WK; Goss G; Klimo P; Feld R; Taylor M
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-27-S8-30. PubMed ID: 9207313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]